ORIGINAL RESEARCH article
Front. Oncol.
Sec. Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1574934
This article is part of the Research TopicNovel Approaches in the Management of Hepatobiliary Pancreatic CancerView all 8 articles
The prognostic impact of Surufatinib for the treatment of advanced pancreatic ductal adenocarcinoma: A single center real-world retrospective study
Provisionally accepted
- Department of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive tumor with a poor prognosis, despite the emergence of chemotherapies such as gemcitabine plus albumin-bound paclitaxel (nab-paclitaxel, AG), unmet medical needs still exist for patients with metastatic PDAC (mPDAC). Surufatinib is a small-molecule tyrosine kinase inhibitor targets vascular endothelial growth factor (VEGFR) 1, 2, 3, fibroblast growth factor receptor 1 (FGFR1), and colony stimulating factor 1 receptor (CSF-1R). This single-center, retrospective study evaluates the potential efficacy of combination therapy containing Surufatinib in advanced or metastatic pancreatic cancer.We conducted a real world retrospective study of mPDAC patients who
Keywords: PDAC, surufatinib, Retrospective study, ICI, tyrosine kinase inhibitor Trial registration: The trial was registered at ClinicalTrials, NCT06378580
Received: 11 Feb 2025; Accepted: 28 Apr 2025.
Copyright: © 2025 Yang, Xie, Shang, Jiang, Ding, LONG and Luo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yanzhen Yang, Department of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou, China
Cong Luo, Department of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.